|Julián Panés © ECCO
Dear ECCO friends,
We are witnessing an exciting period in the development of new therapies for Inflammatory Bowel Diseases. New therapeutic targets, and new classes of drugs, are being integrated into our therapeutic armamentarium. However, when we consider the proportion of patients who respond to induction therapy and, among those, the fraction who achieve remission during maintenance, the percentage of initially treated patients in whom the disease is satisfactorily controlled over one year does not exceed 15%–30%.